News center More...

09 2025-12
Gluetacs Therapeutics Completes First Patient Enrollment in Phase II Clinical Trial of GT919 for POEMS Syndrome
15 2025-11
2025 ASH  |  Gluetacs Discloses GT919 Phase I Clinic Results for Poster Rresentation At the Upcoming 67th American Society of Hematology (ASH) Annual Meeting
22 2025-10
Gluetacs Therapeutics and International Team Reveal a New Mechanism by Which FER Kinase Regulates Head and Neck Squamous Cell Carcinoma Invasion, Providing a Novel Strategy to Overcome Resistance to Targeted Therapy
18 2025-09
Gluetacs Therapeutics Submits Pre-IND Application to the CDE for GT818, a First-in-Class RSK Bifunctional Degrader, for the Treatment of Advanced Malignant Tumors
04 2025-09
Gluetacs Therapeutics was successfully approved for the “2025 Lingang Special Area Patent Navigation Project.”
27 2025-05
Gluetacs was honored with the “Future Star Alumni Enterprise Award” at the 6th University of Chinese Academy of Sciences (UCAS) Alumni Innovation Forum.
15 2025-03
Gluetacs Therapeutics and Fudan University’s Sun Tao/Jiang Chen team develop a PROTAC-loaded nanocapsule targeting BRD4 degradation to break through the radiochemotherapy resistance bottleneck in glioblastoma